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ABSTRACT
Title: Intraoperative Lidocaine Infusions for Postoperative Pain Management
Background: It is known that postoperative pain is a significant cause for patient dissatisfaction
following many types of surgery. Anesthesia professionals search for ways to treat pain from a
multi-modal approach, however postoperative pain continues to be a surgical complication.
Lidocaine infusions have been studied over the last two decades, and although literature has been
controversial for certain surgical populations, research continues to advocate for its use in
anesthesia. Lidocaine has been found to be a potent analgesic, anti-inflammatory, and antihyperalgesia medication that is safe and inexpensive. By reducing the use of opioids and
incorporating lidocaine infusions into practice, patients can achieve better postoperative pain
scores and avoid undesirable side effects such as respiratory depression, sedation, nausea,
vomiting, constipation, and prolonged hospital stays.
Purpose: This independent study is meant to evaluate the current evidence regarding
intraoperative lidocaine infusions. After a thorough review, the goal is to promote the use of
lidocaine infusions to decrease postoperative pain scores, reduce the need for opioids, and
increase patient satisfaction.
Process: A literature review was conducted using the electronic databases CINAHL and
PubMed through the University of North Dakota Health Sciences Library. Additional studies in
reference lists of meta-analyses and randomized controlled trials were also retrieved. Articles
were only included in this literature search if they were published in 2010 or after.
Results: Intravenous lidocaine has been shown to decrease postoperative pain scores
predominantly in patients undergoing abdominal surgery. Intravenous lidocaine infusions should
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be considered a pharmacologic adjunct to achieve enhanced recovery after surgery and allow for
decreased use of opioids intraoperative and postoperative as well.
Implications: In particular surgical populations, utilizing lidocaine infusions intraoperatively
can reduce pain scores, decrease the use of postoperative opioids and acquired side effects, and
increase patient satisfaction. The findings are promising, but further research is indicated.
Keywords: lidocaine, pain, infusion, intraoperative
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Intraoperative Lidocaine Infusions for Postoperative Pain Management
Background
Approximately 80% of patients undergoing a surgical procedure experience postoperative
pain. Although a certain degree of pain is expected, less than half report adequate pain relief after
surgery. Of those patients without adequate pain relief, 10 to 50% percent of patients will
develop chronic pain (Academy of Integrative Pain Management, 2018). For anesthesia
professionals, pain control intraoperatively and postoperatively is of high priority, but not always
easy to accomplish. Traditionally, surgical pain has largely been treated with opioids, and
although there is beneficial use for these medications in surgery, opioids also produce many
unwanted side effects such as respiratory depression, nausea and vomiting, constipation,
delirium, and sedation. Unfortunately, these side effects can lead to increased hospital length of
stay, increased costs, and overall patient dissatisfaction.
Current research seeks to mitigate those unintended side effects through multi-modal
analgesia and targeting various pain pathways and receptors with opioid sparing effects.
Perioperative lidocaine infusions represent one piece of multi-modal anesthesia and have been
shown to decrease pain in the post-surgical patient and decrease opioid requirements. Some
studies have failed to demonstrate that lidocaine has any added benefit in treating postoperative
pain in select surgical populations, however the purpose of this presentation is to highlight
studies that offer strong evidence regarding lidocaine’s use as an analgesic adjunct. This analysis
is meant to provide anesthesia professionals with a thorough review of intraoperative lidocaine
infusions and evidence-based recommendations to enhance treatment of pain, improve surgical
outcomes, and ultimately increase patient satisfaction.
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Case Report
This case report involved a 43-year-old, 140 kg, 173 cm, Caucasian male patient who
presented for an elective laparoscopic gastric bypass Roux-en-Y surgery. Past medical history
was significant for obstructive sleep apnea (on home CPAP), asthma, hypertension,
hyperlipidemia, gastric esophageal reflux disease, morbid obesity (BMI 46.5), and type 2
diabetes. Previous surgical history included laparoscopic adjustable gastric band surgery with
removal, hernia repair, and hand surgery. Current home medications included budesonideformoterol 160-4.5 mcg/puff inhaler used twice daily, hydrochlorothiazide 50 mg daily, losartan
100 mg daily, and a multivitamin daily. Current laboratory values were reported to be within
normal limits with the exception of a mild increase of Hgb A1C at 6.3 and creatinine 1.16. Chest
x-ray and EKG were normal.
Physical findings revealed a morbidly obese male who was assigned an ASA physical
status class 3 primarily due to his body habitus. Vital signs were within normal limits. Cardiac
exam was normal with a regular rhythm, no murmurs or rubs, breaths sounds were clear, and his
mental status was alert and oriented. Pre-anesthetic evaluation included a Mallampati 3 airway,
short neck with full neck range of motion, small mouth opening with adequate jaw protrusion,
and no dental history. The patient was NPO for greater than 8 hours. Previous anesthesia records
were reviewed and there was no history of previous airway management issues or anesthetic
complications.
Preoperatively, a scopolamine patch and gabapentin 600 mg were administered. A 20gauge peripheral IV was placed and an infusion of lactated ringers was initiated. The patient was
transported to the operating room and placed supine on the operating table with a wedge ramp.
Standard monitors consisting of 5-lead EKG, blood pressure, oxygen saturation, and end-tidal
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CO2 detection sampling were applied. Pre-oxygenation was administered using 100% FiO2 via
mask for approximately 5 minutes. General anesthesia was induced with intravenous midazolam
2 mg, fentanyl 100 mcg, lidocaine 140 mg, rocuronium 5 mg, propofol 250 mg, ketamine 30 mg,
and succinylcholine 140 mg. The video laryngoscope was electively used because of his small
mouth opening. A grade 1 view was obtained, and a size 8 endotracheal (ETT) was passed
without difficulty. ETT placement was further verified using end-tidal CO2 monitoring and lung
auscultation. Due to the patient’s asthma history, 3 puffs of albuterol were administered via the
ETT after intubation. The patient was placed on volume control ventilation and general
anesthesia was maintained with desflurane at 6% with a mixture of 1L/min oxygen and 1L/min
air. A dexmedetomidine infusion was initiated after intubation with a bolus of 50 mcg over 10
minutes with a continuous infusion at 0.5 mcg/kg/hour. A continuous lidocaine infusion was
added at 2 mg/min following induction but prior to incision. The patient also received
magnesium 2 g, acetaminophen 1 g IV, enoxaparin 40 mg, and cefazolin 3 g prior to incision. No
additional doses of narcotics were used intraoperatively.
Abdominal muscle relaxation was required, and multiple paralytic doses of rocuronium
were given without effect. This warranted switching to cisatracurium 2 mg bolus doses, and
adequate muscle relaxation was achieved. Intraoperatively, the patient required multiple doses of
phenylephrine and ephedrine, and a phenylephrine infusion was started. The patient also received
dexamethasone 4 mg after induction and ondansetron 4 mg at the end of the case. The lidocaine
and dexmedetomidine infusions were stopped when the surgeon began closing the abdomen. The
patient was fully reversed after surgical closure with glycopyrrolate 0.4 mg and neostigmine 5
mg. Ketorolac 30 mg was given prior to extubation. After paralytic reversal and spontaneous
breathing effort on the ventilator, the patient was extubated 284 minutes after incisional cut time
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without difficulty. A nasal cannula was applied with 4 L oxygen, and the patient was transferred
to the PACU. There was minimal EBL, and the patient received a total of 1800 ml of lactated
ringers. In the recovery room, fentanyl 50 mcg was given twice for moderate pain, and a fentanyl
PCA was initiated at 10 mcg/10min with no continuous rate. The patient was also started on
scheduled ketorolac 30 mg every six hours.
Later that afternoon on the inpatient unit, the patient was found to be resting comfortably,
pain rated at 4/10. The patient had been out of bed and walking to the bathroom. The patient’s
vital signs were WNL, and patient was not SOB or in any acute distress. His abdomen was soft,
distended, and slightly tender to palpation. According to the chart, on POD 1, the patient
continued to rate his pain 4/10, reported to have slept well, was ambulating in the halls, passing
gas, and his PCA had been discontinued. There had been no increase in his PCA rate. The patient
remained on scheduled ketorolac and prn oxycodone and was discharged on POD 2.
Literature Search
Method
A literature search regarding intraoperative lidocaine infusions was performed through
the University of North Dakota’s Health Science Library using the following terms: (lidocaine
AND infusion AND pain AND intraoperative). Electronic databases included CINAHL and
PubMed. When using the above keywords, 15 articles were found in CINAHL. In PubMed,
lidocaine was entered into the MESH database, the same keywords were added to the search, and
23 articles were found in PubMed. Of those articles, 8 articles were used in this literature review.
Additional studies were retrieved from reference lists of meta-analyses and randomized
controlled trials. The literature search of randomized control trials and meta-analyses was limited
to 2012 to the present date.
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Discussion
Pain Pathway
In order to understand the role of local anesthetics in pain management, it is imperative to
dive into the elements of the pain pathway. The International Association for the Study of Pain
(IASP) defined pain as “an unpleasant sensory and emotional experience associated with actual
or potential tissue damage” (2018). The first stage of the pain pathway involves pain
transduction, which occurs when a noxious stimulus is transformed into an action potential. This
occurs when specialized sensory receptors, called nociceptors, respond to noxious stimuli and an
electrical impulse is generated. Nociceptors are found on A-delta and C nerve fibers, meaning
they are the primary nerve fibers that are responsible for conducting pain to the brain. These
nerve fibers are distributed in skin, viscera, muscles, joints, and meninges (Reddi & Curran,
2013). A-delta nerve fibers have a large diameter, are lightly myelinated and conduct nerve
impulses rapidly, while C fibers have a smaller diameter, are unmyelinated, conduct nerve
impulses slowly, and innervate visceral internal organs (Nagelhout & Elisha, 2018). When a
noxious stimulus is sensed, it causes a release of chemical mediators and neurotransmitters such
as substance P, glutamate, bradykinin, histamine, serotonin, prostaglandins, and cytokines. These
mediators and neurotransmitters directly stimulate peripheral nociceptors and cause an influx of
sodium ions to enter the nerve fiber membrane and create depolarization. This creates an action
potential and pain is generated (Nagelhout & Elisha, 2018). Once the action potential is
generated, it is carried from the periphery to the central nervous system. Local anesthetics take
effect at the beginning of the pain pathway and prevent the conversion of noxious stimuli into an
action potential. In this way, the sensory input cannot be transmitted to the brain, and
consequently analgesia occurs (Nagelhout & Elisha, 2018).
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The second stage of the pain pathway involves pain transmission. The spinothalamic
track is a pathway that transports pain signals from the trunk and lower body via the first,
second, and third-order neurons. Primary afferent neurons are responsible for detecting noxious
stimuli and moving the sensory input from the nociceptors to the gray matter of the dorsal horn
in the spinal cord. The dorsal horn can be divided into ten layers called Rexed Laminae. A-delta
and C fibers transfer information in Rexed lamina 1 and 2, in addition to projections to other
laminae. First and second-order neurons connect in the dorsal horn, and second order neurons are
responsible for transmitting pain signals from the spinal cord to the brainstem in the contralateral
spinothalamic tract. Third order neurons conduct pain impulses from the brain stem to the
thalamus, cortex, and higher levels of the brain and terminate in the somatosensory cortex where
the perception of pain occurs. Third order neurons also have an important role in the descending
inhibitory pain pathway (Reddi & Curran, 2013). There is a synaptic cleft between the ends of
nerve fibers and the dorsal horn neurons. Excitatory neurotransmitters such as glutamate,
substance P, bradykinin, and nitrous oxide are released to transmit the pain impulses across the
synaptic cleft. Then the pain signals are transmitted from the spinal cord to the brain stem and
thalamus via the spinothalamic pathway. The third stage of the pain pathway occurs when pain
impulses reach the thalamus and pain is processed (Kumar, Gupta, Kaleem, & Pandey, 2014).
The fourth stage in the pain pathway involves pain modulation. Modulation involves
altering neural afferent activity such as pain inhibition or enhancing of the pain signal. Pain is
altered along the descending pain pathway in the location of the periaqueductal grey (PAG) in
the midbrain (Reddi & Curran, 2013). The PAG contains a high concentration of endogenous
opioids and other inhibitory neurotransmitters such as serotonin, acetylcholine, and oxytocin
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which serve as a natural way to “turn off” pain (Kumar, Gupta, Kaleem, & Pandey, 2014). Many
analgesia pharmaceuticals such as opioids occur at this component of the pain pathway.
Lidocaine
Mechanism of Action
After reviewing the physiology of the pain pathway, lidocaine’s mechanism of action can
be delineated. Intravenous lidocaine is known to have analgesic, anti-inflammatory, and antihyperalgesia properties, but its role in pain begins at the cellular level. Lidocaine produces
analgesia through the involvement of sodium channel blockade, acetylcholine in cerebral spinal
fluid, NMDA receptors, and by reducing inflammatory responses. Lidocaine contains an
aromatic ring with an amine at opposite ends of the molecule and is separated by a hydrocarbon
chain and an amide bond. This amide bond structure classifies lidocaine as an amide local
anesthetic. Lidocaine’s primary mechanism of action involves binding to the peripheral and
central voltage gated sodium channel’s inner core of the alpha subunit (NYSORA, 2019a).
Sodium channels help maintain an electrical gradient across the neuronal cell membrane,
initiate and facilitate action potentials, and are required for transmission of peripheral
nociceptive stimuli to reach the brain. Sodium channels can exist in “resting,” “open,” and
“inactivated,” states, and supply both skeletal and cardiac muscle and neuronal tissue. At rest,
sodium channels are in the closed state, and sodium ions are highly concentrated in the
extracellular space. When an action potential occurs, neuronal sodium channels quickly open
which allows extracellular sodium to enter the cell, making the inside of the cell positive and
depolarization occurs (NYSORA, 2019a). Anesthesia occurs when lidocaine (along with all local
anesthetics) binds to sodium channels, prevents the sodium influx and action potential, and
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results in conduction blockade and a selective depression of pain transmission in the spinal cord
so the brain cannot sense painful stimuli (Yon et al., 2013 & Peng et al., 2016).
When lidocaine is administered intravenously, it also increases the amount of
acetylcholine in the cerebrospinal fluid. This increase in acetylcholine inhibits the descending
pain pathway resulting in analgesia. It is thought that lidocaine contributes to a release of
endogenous opioids and an inhibition of the excitatory neurotransmitter glycine (Ibrahim, Aly, &
Farrag, 2018).
Lastly, lidocaine has potent anti-inflammatory effects by inhibiting the N-methyl-daspartate (NDMA) receptor. Noxious events, such as surgery, create hyperexcitability in the
NMDA receptors and the release of cytokines in the central nervous system. When lidocaine
blocks NMDA receptors, there is an inhibition of inflammatory mediators and a decrease in the
post-synaptic depolarization which results in decrease of pain signaling to the brain. When
lidocaine can reduce cytokine production, there is a decreased inflammatory response, less
windup of pain, and a decreased risk for hyperalgesia (Ibrahim, Aly, & Farrag, 2018).
Additionally, when lidocaine reduces the inflammatory processes in the bowel by inhibiting
cytokine secretion, there is a more rapid return of bowel function on top of decreased pain.
Along with lidocaine’s unique role in pain, it also has a short half-life and favorable
safety profile compared to esters, which makes it the local anesthetic of choice for intravenous
administration. Lidocaine has a rapid onset of approximately 45-90 seconds, and the initial halflife for bolus administration is approximately 10 minutes due to rapid liver metabolism and
redistribution (Gordon & Schroeder, 2008). When lidocaine infusions are discontinued, plasma
levels decrease quickly. With a continuous infusion, the half-life is estimated to be about 1.5 to 2
hours, and in healthy patients there is no drug accumulation (Eipe, Gupta, & Penning, 2016).
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Lidocaine is metabolized in the liver and clearance is highly dependent on hepatic blood flow
and enzyme function. Lidocaine should be used with caution in patients with decreased hepatic
blood flow, such as in heart or liver failure or patients taking cytochrome inhibitor medications.
Likewise, renal failure increases volume of distribution of amide local anesthetics and can
increase metabolic by-products (NYSORA, 2019a). Ultimately, dosages should be reduced by
50% in patients older than 70 years of age or with liver disease, in order to avoid complications
such as CNS depression, seizures, drowsiness, bradycardia, and hypotension (Gordon &
Schroeder, 2008).
Side Effects
Although side effects from a lidocaine infusion have been shown to be of low risk, it
remains vital for anesthesia practitioners to be aware of complications and signs of toxicity. Mild
symptoms, often associated with low lidocaine plasma concentrations, consist of restlessness,
tinnitus, circumoral numbness, vertigo, or tremors. More serious side effects include drowsiness,
hypotension and tachycardia, and can progress to bradycardia, arrythmias, seizures,
unconsciousness, coma, and cardiovascular collapse. According to NYSORA, “most local
anesthetics will not cause cardiovascular toxicity until the blood concentration exceeds three
times that necessary to produce seizures” (2019b).
Intraoperative Use of Lidocaine
Benefits from intraoperative lidocaine infusions have been controversial, however there
has always been success reported in the abdominal surgical population. The first study involves a
prospective, double-blind, placebo-controlled trial using 36 patients undergoing subtotal
gastrectomies who received a lidocaine infusion with a bolus dose of 1.5 mg/kg followed by a
continuous infusion of 2 mg/kg/hour. The study showed that these patients had lower pain scores
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24 hours after surgery, and fentanyl consumption was significantly lower in this group until 12
hours postoperatively compared to a normal saline placebo infusion. No differences were found
related to nausea or hospital length of stay (Yon, Choi, Kang, Park &Yang, 2013). Two years
later, another randomized, double-blind, placebo-controlled study was conducted. This study
included 50 patients undergoing scheduled laparoscopic colectomies and found similar results.
The same lidocaine dose was used as above, and again, patients in the lidocaine group reported
significantly lower pain scores 24 hours postoperatively and required significantly less fentanyl
until 12 hours after surgery compared to a normal saline placebo group. Patients receiving
lidocaine infusions in this study also had fewer complaints of nausea and higher recovery
satisfaction scores (Ahn et al., 2015). In both studies, patients in the lidocaine groups were found
to have lower C-reactive protein levels postoperatively signifying that lidocaine possesses antiinflammatory properties. It is also important to note that none of the patients in either the
lidocaine or placebo group received pre-medications or any additional analgesics intraoperatively
other than lidocaine (Ahn et al., 2015 & Yon et al., 2013).
The use of intraoperative lidocaine has also been studied in patients undergoing bariatric
surgery. A prospective randomized, double-blind, placebo-controlled clinical trial consisting of
50 patients undergoing laparoscopic bariatric surgery was reviewed. The study found that when
an intraoperative lidocaine infusion was used with a bolus of 1.5 mg/kg followed by a 2
mg/kg/hour infusion, patients reported higher postoperative quality of recovery scores, had lower
postoperative opioid requirements, and fewer complaints of nausea when compared to a normal
saline placebo group. Patients in both groups were pre-medicated with 0.04 mg/kg IV midazolam
and given propofol 1-2 mg/kg, remifentanil 0.1 mcg/kg/min IV infusion, and succinylcholine 1-2
mg/kg for induction. Anesthesia maintenance was controlled with remifentanil titrated to 20% of
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blood pressure baseline with desflurane titrated to a BIS of 40-60, and rocuronium. When
laparoscopic instruments were removed, hydromorphone 0.01 mg/kg was given. Multi-modal
analgesic techniques may be most important in this morbidly obese patient population because
opioids are often accompanied by adverse respiratory complications such as hypoventilation and
hypoxemia which can complicate postoperative recovery (De Oliveira Jr. et al., 2013).
Multiple randomized controlled trials have also discovered the significant impact
intravenous lidocaine infusions have on laparoscopic cholecystectomy patients. A randomized,
blinded, placebo-controlled trial of 71 patients concluded that when using a lidocaine bolus of
1.5 mg/kg before skin incision followed by an infusion of 2 mg/kg/hour, patients in the lidocaine
group reported significantly lower pain scores compared to the normal saline placebo group at 2
hours and 6 hours postoperatively. Additionally, participants in the lidocaine group had
significantly longer times for the request of the first dose of analgesic compared to the normal
saline group, and the total mean analgesic requirements after surgery were significantly less.
This study also found that times to first flatus and bowel movement were significantly shorter in
patients who received lidocaine. This is noteworthy considering abdominal surgery patients often
have complications such as ileus, nausea, vomiting, and constipation. This particular study also
measured concentrations of inflammatory markers such as serum IL-6, IL-8, IL-1ra before
induction of anesthesia, at the end of surgery, and at 12 hours postoperatively. It was found that
the levels of serum IL-6 and IL-8 in the lidocaine group at the end of surgery and 12 hours
postoperatively were lower than the control group, reaffirming that lidocaine exhibits an antiinflammatory quality which could be responsible for the decreased times for return of bowel
function (Song, Sun, Zhang, Li, & Yang, 2017).

INTRAOPERATIVE LIDOCAINE INFUSIONS

16

A meta-analysis of 5 randomized controlled trials involving 274 patients was conducted
on patients undergoing laparoscopic cholecystectomies who also received intravenous infusions
of lidocaine for pain management. Of the 5 reviewed trials, 4 trials used a lidocaine bolus of 1.5
mg/kg followed by a continuous infusion of 2 mg/kg/hour, and 1 trial used a lidocaine bolus of
1.5 mg/kg but increased the continuous rate to 3 mg/kg/hour. The meta-analysis found that the
lidocaine infusion group had significantly lower pain scores at 12 hours, 24 hours, and 48 hours
after surgery. Patients in the lidocaine group were also found to have reduced opioid
consumption and fewer adverse effects (Zhao et al., 2018).
Lastly, a double-blind, placebo-controlled study with 45 participants found that when
using a lidocaine bolus of 1 mg/kg on induction followed by a 2 mg/kg/hour infusion for patients
undergoing laparoscopic gynecological procedures, patients had decreased analgesic
requirements, but the trial failed to achieve statistical significance when compared to the normal
saline placebo group. However, the patients receiving lidocaine has a significantly decreased
time to first flatus (Grady, Clark, Lenahan, Oudekerk, Hawkins, Nezat, Pellegrini, 2012). This is
one of the few studies that utilized a lidocaine bolus of only 1 mg/kg, and it must be questioned
if this decrease in bolus dose could possibly affect outcomes.
There is substantial evidence that supports the use of lidocaine infusions to decrease
postoperative pain in patients with abdominal surgeries, and other surgical populations have also
experienced positive effects. Intraoperative lidocaine has also proved to be effective in patient
populations undergoing spinal fusion surgery, supratentorial brain tumor surgery,
laminectomy/discectomy, and mastectomies. A recent prospective, randomized, double-blinded
study involving a total of 40 patients undergoing spinal fusion surgery demonstrated that
administering a lidocaine bolus of 2 mg/kg before induction followed by a continuous rate of 3
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mg/kg/hour until the end of surgery reduced the postoperative pain scores for up to 3 months,
reduced morphine consumption in the first 24 hours postoperative, and prolonged the time to
first request for additional pain medication compared to a normal saline placebo group. In this
study, all participants received an anesthesia regimen of propofol, Cisatracurium, isoflurane,
ketorolac, fentanyl, and acetaminophen in equal doses (Ibrahim, Aly, & Farraq, 2018).
In patients having supratentorial brain tumor surgery, it was found that lidocaine
significantly decreased the proportion of patients with acute pain in the PACU. A prospective,
randomized, double-blinded study with 80 patients found that when using an intraoperative
lidocaine with a bolus of 1.5 mg/kg after induction and an infusion of 2 mg/kg/hour until the end
of surgery, the incidence of “no pain” was higher in the lidocaine group than the normal saline
placebo group prior to transferring out of the PACU. There were no patients with moderate or
severe pain in either group Anesthesia between the groups also consisted of using midazolam
0.05 mg/kg for premedication followed by Sufentanil 0.2 mcg/kg, propofol 1.5-2.5 mg/kg, and
rocuronium 0.6 mg/kg for induction. Anesthesia was maintained using propofol, sevoflurane,
and a remifentanil infusion (Peng et al., 2016). Opioid sparing effects in this neuro-surgical
population are even more important as surgeons often require neurological assessments
immediately after surgery.
Lidocaine has also been shown to decrease pain and reduce the consumption of opioids in
patients undergoing laminectomy and discectomy lumbar surgery. A prospective, randomized,
double-blinded, and placebo-controlled clinical trial using 51 subjects agreed that lidocaine
infusions contribute to decreased postoperative pain scores, reduced fentanyl consumption, and
decreased length of stay when compared to a normal saline placebo group. The lidocaine bolus
was given at 1.5 mg/kg and the infusion was dosed at 2 mg/kg/hour until the end of surgery. The
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2 groups received the same anesthetic protocol, which consisted of thiopental 5 mg/kg and
rocuronium 0.6 mg/kg for induction. Anesthesia was maintained using 2 to 3% sevoflurane with
1.5 L/min nitrous oxide and 1.5 L/min O2 mixture. No premedications were given. There is no
note of any opioids or other analgesics being administered intraoperatively. The lidocaine group
reported less pain than the normal saline group for up to 48 hours, and the patients also had a
decreased hospital length of stay (Kim et al., 2014).
Lastly, lidocaine infusions have been shown to improve postoperative quality of
recovery, reduce intraoperative opioid requirements, and improve chronic pain for patients
undergoing mastectomy for breast cancer. A prospective, double-blind, randomized clinical trial
using 116 female patients utilized a lidocaine bolus of 2 mg/kg after induction followed by an
infusion of 2 mg/kg/hour. The study compared intraoperative lidocaine, magnesium, and normal
saline groups. Magnesium is being incorporated into anesthesia as another multi-modal
technique because it is also a NMDA receptor antagonist and has anti-nociception mechanisms.
The intraoperative magnesium was initiated with a bolus of 20 mg/kg followed with a continuous
infusion of 20 mg/kg/hour. The intraoperative lidocaine group had favorable effects on early
postoperative recovery and higher quality of recovery scores when compared to the magnesium
and normal saline groups. The quality of recovery survey included dimensions such as physical
comfort, emotional state, physical independence, psychological support, and pain. The study also
showed that lidocaine and magnesium did not have significant differences in reducing
intraoperative opioid consumption, but they both proved superior to normal saline infusions
(Kim et al., 2017).
While many reputable trials appear to decrease postoperative pain scores and reduce
opioid requirements, lidocaine’s use in other surgical procedures can be controversial. Each
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surgery possesses a different level of triggered pain and may alter the effects of lidocaine.
Although the previously mentioned study argues that lidocaine infusions can be effective for
mastectomy patients, a study published in the same year disagrees. In this particular trial, it was
found that there were no differences in quality of recovery, pain scores, or opioid consumption
for mastectomy patients at periods of 24 hours post operation up to 6 months. The study
examined 148 patients who were randomly divided into 2 groups. One group received 1.5 mg/kg
bolus of IV lidocaine followed by an infusion of 2 mg/kg/hour, and the placebo group received a
normal saline bolus and infusion at the same rates. Each group received identical anesthetic
regimens of propofol, sevoflurane, remifentanil infusions, and hydromorphone at the end of
surgery. It was found that pain burden, opioid consumption, and quality of recovery were no
different at 24 hours postoperative when comparing the lidocaine and normal saline groups
(Kendall et al., 2017). Although this study includes recent data, all surgical study participants
received intraoperative opioid medications which could affect the validity of the study when
compared to studies that do not use any additional opioids. One must question whether the
lidocaine infusion would show any benefit when compared to normal saline if the patient is
already well narcotized.
Another study argued that lidocaine infusions are not effective for mastectomy patients.
A 2016 meta-analysis of randomized control trials found that lidocaine infusions did not affect
postoperative pain scores at rest or activity 2 hours to 3 days when compared to a placebo of
normal saline. However, at 72 hours postoperative, the lidocaine group required fewer
analgesics. There was also a trend of lower pain scores in the lidocaine group at 2 hours
postoperative and 48 hours, but the evidence was not statistically significant. The meta-analysis
included a total of 84 patients randomized to the lidocaine group, and 83 patients randomized to

INTRAOPERATIVE LIDOCAINE INFUSIONS

20

the placebo group. The study concluded that lidocaine may produce more significant benefits in
patients undergoing abdominal surgery because the intensity of pain is higher than many other
surgeries that have been studied (Chang et al., 2016).
When comparing all of the above studies to the patient in the case report, it was found
that the majority of studies used a lidocaine bolus of 1.5 mg/kg followed by a continuous
infusion of 2 mg/kg/hour. The case report patient received a lidocaine bolus of 1 mg/kg during
induction followed by a continuous infusion of 2 mg/min, which was not weight based and
underdosed based on the patient’s body weight. In addition to a lidocaine infusion, the case
report patient also received preoperative acetaminophen and gabapentin and other multi-modal
agents in surgery including ketamine, magnesium, a dexmedetomidine infusion, and ketorolac,
which all could have contributed to his recovery. Many reviewed studies did not include other
multi-modal medications when testing the efficacy of lidocaine. Like the studies regarding
abdominal surgery, the case report patient had well controlled pain and limited narcotic use
postoperatively. Additionally, the case report patient did not have preoperative or postoperative
C-reaction protein levels drawn so the inflammatory response could not be assessed.
Even though most studies used a consistent lidocaine dose, many studies were vague
regarding when the lidocaine bolus was started, how long the bolus infused, and precise times for
infusion discontinuation which could affect outcomes. In most studies, it was standard for
postoperative patients to receive a narcotic PCA. Although this may seem counterintuitive, only
demand dosing was ordered and significantly less total narcotic PCA was required in the
lidocaine groups (Ahn et al., 2015, De Oliveira Jr. et al., 2013, Kim et al., 2014, Peng et al.,
2016, & Yon et al., 2013). Most studies assessed patients’ pain using a Visual Analog Scale
(VAS) with 0 meaning “no pain” and 10 meaning the “worst possible pain”. Pain was evaluated
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at slightly different intervals, but common times included 0, 2, 4, 8, 12, 24, and up to 48 hours
post-surgery. Most studies collected data regarding lidocaine’s effect on postoperative pain
scores, time until request for first pain medication, and total opioid dosing postoperatively (Ahn
et al., 2015, De Oliveira Jr. et al., 2013, Khan et al., 2016, Kim et al., 2014, Kim et al., 2017,
Peng et al., & Yon et al., 2013).
One inconsistency that was noted while reviewing the literature was that studies failed to
describe whether lidocaine should be dosed per total body weight, ideal body weight, or adjusted
body weight. For the patient in the case report, total body weight was used for dosing. A
lidocaine bolus of 140 mg was given but only a 1 mg/kg calculation was used. The patient
received a continuous lidocaine infusion at 2 mg/min (120 mg/hour) instead of the recommended
2 mg/kg/hour. If 2 mg/kg/hour would have been used and based on TBW, the continuous dose
would have increased from 120 mg/hour to 280 mg per hour. A dose of 2 mg/min would
underdose a patient as long as they weigh over 60 kg. De Oliveira Jr. et al. (2013) is the only
study that advises using adjusted body weight (ABW) for dosing lidocaine infusions. The
calculation is [ideal body weight (IBW) + 0.4 x (actual body weight- IBW)]. This is an important
consideration when dosing lidocaine infusions because a dose based on TBW can easily be
doubled compared to IBW, especially for obese patients.
Maximum Safe Doses
In order to safety administer intravenous lidocaine infusions, it is imperative anesthesia
professionals understand how to calculate maximum dosages for lidocaine infusions and other
possible local anesthetics used by the surgeon. The maximum dose for plain lidocaine is 4
mg/kg and increases to 7 mg/kg if epinephrine is added. It is important to remember that the
overall maximum dose for lidocaine is 300 mg, even if the dose per kilogram exceeds this. The
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maximum dose is also calculated as a “per hour” guideline, which means each hour an additional
300 mg can be given safely. For example, if the patient is 75 kg and a bolus of 1.5 mg/kg (112.5
mg) and infusion of 2 mg/kg/hour (150 mg) is used, theoretically the patient would receive 262.5
mg after the first hour. The lidocaine bolus is often given during induction and takes the place of
a bolus given to relieve propofol induced pain or to blunt the SNS response of airway
manipulation with intubation. After the first hour, a continuous infusion rate of 2 mg/kg/hour
would equal 150 mg for this patient of 75 kg. This would mean the patient is receiving 50% of
the local anesthetic maximum dose, therefore the surgeon is able to use 50% of the maximum
dose of local anesthetic for skin infiltration at the end of surgery. For example, if the surgeon
injects 0.25% bupivacaine with epinephrine during incision closure, the maximum dose is 3
mg/kg. The patients calculated max dose for bupivacaine is 225mg, and 50% of that is 112.5 mg.
In order to calculate the amount in milliliters, the dose must be divided by the local anesthetic
concentration. If the local anesthetic is 0.25% bupivacaine, 45 ml can still be injected safely.
Additionally, when calculating maximum doses, it can be theorized that a continuous infusion is
constantly being metabolized at a steady rate, meaning at the end of each hour, not all of the
local anesthetic is adding up at one time.
In some cases, local anesthetics can reach their maximum doses quickly which poses a
greater risk for lidocaine toxicity, however none of the articles found evidence to support this
fear. Specifically, authors noted that no blood samples showed toxic levels and no cardiovascular
or neurological adverse events occurred (Ahn et al., 2015, De Oliveira Jr. et al., 2013, & Peng et
al., 2016). Lidocaine toxicity is likely to be seen at plasma concentration of 5mcg/ml. However,
when a bolus of 1-2 mg/kg is administered and then followed with a continuous infusion of 1.5
mg/kg, the corresponding plasma concentration is only at 2 mcg/ml, and the risk of toxicity is
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low (Lauretti, 2008). In this way, practitioners need to be aware of lidocaine toxicity, risks, and
treatment, however, lidocaine infusions have a favorable safety profile and should not be avoided
because of the fear of overdosing.
Although reaching critical levels with lidocaine infusions is rare, it remains imperative
for anesthesia professionals to be aware of local anesthetic systemic toxicity (LAST) and
treatment options. Variables that increase the risk of LAST include using the wrong local
anesthetic drug or dosage, extremes of age, patient comorbidities, small muscle mass, liver or
kidney failure, and malnutrition. Side effects of local anesthetics and more serious signs of
LAST are mentioned previously. In terms of LAST, prevention is key. It is imperative to know
maximum safe doses, use proper monitoring, careful selection of local anesthetic and attention to
concentration, and have adequate preparation for possible resuscitation (Nagelhout & Elisha,
2018).
Treatment of LAST involves the need for immediate recognition followed by seizure
management, advanced cardiac life support (ACLS) and prompt administration of 20% lipid
emulsion. The local anesthetic should be stopped, and one should seek help. Benzodiazepines are
the first line treatment for seizure activity. If patients are unstable, airway management and
circulatory support is required (NYSORA, 2019b). Reversal of LAST is treated with lipid
emulsion and CV collapse will occur if lipids are not administered. If the patient weighs greater
than 70 kg, a 20% lipid emulsion bolus of 100 ml bolus is given over 2-3 minutes followed by an
infusion of 200-250 ml over 15-20 minutes. If patients remain unstable, bolus doses can be
repeated twice, and infusion rates can be doubled. If the patient weighs less than 70 kg, a bolus
dose of 1.5 mg/kg is given followed by an infusion of 0.25 ml/kg/min until symptoms resolve.
There is a dosing limit of 12 ml/kg which is particularly important in the small child. After a
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LAST incident, patients should be continuously monitored 4-6 hours after a cardiovascular event
or at least 2 hours after a CNS event. There is a LAST algorithm that should be available and
familiar to anesthesia providers who administer local anesthetics (American Society of Regional
Anesthesia and Pain Medicine, 2018).
Practice Recommendations
After completing a thorough literature review, there are two main practice
recommendations. First, anesthesia professionals should consider the use of lidocaine infusions
with a bolus and continuous infusion for any abdominal surgery. According to the most current
literature, the recommended intravenous infusion should include an initial bolus of 1.5 mg/kg
followed by an infusion of 2 mg/kg/hour (Zhao et al, 2018). The lidocaine infusion bolus should
be initiated immediately prior to induction and followed by a continuous infusion until wound
closure. A bolus is always recommended because a continuous infusion alone will take 4-8 hours
to achieve stead state plasma concentration which is often much longer than common surgical
times (Eipe, Gupta, & Penning, 2016). Other opioids can be used intraoperatively and
postoperatively, but practitioners may find that less opioids are required. Lidocaine infusions
should be predominantly considered for patients undergoing abdominal surgery because data is
most consistent with this specific population. Additionally, the infusions should be reserved for
cases greater than one hour where larger amounts of opioids are generally needed.
The second, and possibly most important recommendation, includes the need for further
research in many areas. Additional high-quality studies need to be performed with larger sample
sizes in order to continue to validate the current use of lidocaine. Further studies need to include
comparisons regarding different lidocaine doses and timing of initiation and discontinuation of
the infusion. Although most randomized controlled trials utilized a lidocaine bolus of 1.5 mg/kg
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followed by a continuous infusion of 2 mg/kg/hour, the optimal perioperative treatment protocol
is unknown. Lastly, there also needs to be further research conducted regarding dosing on TBW
compared to IBW or ABW as a way to mitigate unnecessary side effects.
Conclusion
Pain is complex and an unwanted component of almost all surgical procedures.
Intraoperative lidocaine administration should strongly be considered when formulating a multimodal approach to pain management within an anesthetic plan. Intraoperative lidocaine has
proven to be a safe, valuable, and a cost-effective intervention that can decrease postoperative
pain, reduce the use of opioids, and increase overall patient satisfaction.
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